QUANTRO Therapeutics extends collaboration with Boehringer Ingelheim
Novel targets in oncology
Advertisement
QUANTRO Therapeutics announces the extension of its strategic collaboration with Boehringer Ingelheim. Building on the progress made in the first phase and the agreement signed in 2022, this two-year extension will continue the joint research and development program to advance the development of first-in-class drug candidates against cancer-associated transcription factors.
Cancer remains one of the leading causes of death worldwide and the need for novel and effective treatments is high. Despite advances in cancer therapy, many patients continue to face limited treatment options and unfavorable prognoses. The aim of this partnership is to tackle these challenges. To this end, innovative therapeutics are to be developed that target mechanisms of cancer that were previously considered therapeutically inaccessible.
"We are very pleased to continue our successful collaboration with Boehringer Ingelheim to achieve our shared goal of improving the lives of cancer patients," said Dr. Michael Bauer, CEO of QUANTRO. "The identification of functionally validated targets for therapeutically difficult-to-access transcription factor targets using our HTS screening platform validates the precision, power and maturity of our innovative, time-resolved transcriptomics platform. We look forward to continuing to push the boundaries of what is possible in transcriptomic drug discovery."
Transcription factors are key regulators of gene expression and play a crucial role in the development and progression of cancer. Despite their relevance, they have so far been largely inaccessible for drug development due to technical limitations and the lack of precision of conventional test methods. These methods are unable to adequately identify direct transcriptional changes caused by potential drugs at early time points (e.g. as early as one hour after administration). QUANTRO's proprietary, time-resolved transcriptomics platform overcomes these limitations by enabling precise characterization of transcriptional changes over time to uncover actionable disease-causing mechanisms.
To date, Quantro has achieved technical proof of concept, cross-validation of its HTS screening technology and the identification of functionally validated hits against previously undruggable transcription factors. This was followed by the successful completion of the company's largest dual-target transcriptomic screening campaign to date, in which over 350,000 compounds were evaluated to identify candidates that specifically target selected transcription factors.
Now, QUANTRO will continue to utilize its time-resolved transcriptomics platform to jointly advance the discovery of first-in-class small molecule inhibitors of select oncogenic transcription factors.
Under the terms of the agreement with Boehringer Ingelheim, QUANTRO has already received payments and is eligible for additional success-based R&D, regulatory and commercial milestone payments with an estimated total value of approximately €500 million. Further details on the terms of the collaboration were not disclosed.
QUANTRO retains full ownership of its technology platform and internal drug discovery programs targeting additional transcription factors beyond the scope of the collaboration.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department research and development
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
Giles introduces AI agent to accelerate healthcare and life science research - AI tool connects researchers to verified medical and life sciences global databases, enabling accurate extraction and summarisation of academic papers, journals, and articles
Faster and more reliable crystal structure prediction of organic molecules
Elevated hormone flags liver problems in mice with methylmalonic acidemia - Study findings can immediately be applied to human patients with the disease
Investigational monoclonal antibody to treat Ebola is safe in adults
NIH clinical trial of remdesivir to treat COVID-19 begins
APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease
CORAT Therapeutics obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101 - COR-101 is a human antibody that blocks virus infection by binding to the spike protein
New muscle therapy gets fast-track boost - Berlin start-up could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process
SAS accelerates delivery of novel medicines using AI and analytics - Cooperation with AstraZeneca for more innovation in clinical research
Gentle protein purification at the touch of a button - i3 Membrane revolutionizes the separation of biological agents
Bio-based plastics for infusion bags - Frankfurt research team develops sustainable alternative to medical products made from crude oil in cooperation with bioplastics start-up BIOVOX
